TY - JOUR
T1 - Estrogen receptor
T2 - A paradigm for targeted therapy
AU - Damodaran, Senthil
AU - Hortobagyi, Gabriel N.
N1 - Publisher Copyright:
© 2021 American Association for Cancer Research
PY - 2021/11/1
Y1 - 2021/11/1
N2 - Nearly two-thirds of breast cancers overexpress estrogen receptors, and endocrine therapy is considered the backbone of systemic therapy both in early and advanced settings. While this is now widely recognized in clinical practice, this is the culmination of outstanding contribution of many investigators and patients. Indubitably, estrogen receptor targeting has had the most impact among targeted therapies and has significantly affected patient survival. In this commentary, we revisit a landmark article published in Cancer Research in 1977 by Knight and colleagues, which laid the groundwork for the use of estrogen receptors in prognostication and adjuvant treatment selection, as well as some of the key breakthroughs in estrogen receptor biology that span more than a century.
AB - Nearly two-thirds of breast cancers overexpress estrogen receptors, and endocrine therapy is considered the backbone of systemic therapy both in early and advanced settings. While this is now widely recognized in clinical practice, this is the culmination of outstanding contribution of many investigators and patients. Indubitably, estrogen receptor targeting has had the most impact among targeted therapies and has significantly affected patient survival. In this commentary, we revisit a landmark article published in Cancer Research in 1977 by Knight and colleagues, which laid the groundwork for the use of estrogen receptors in prognostication and adjuvant treatment selection, as well as some of the key breakthroughs in estrogen receptor biology that span more than a century.
UR - http://www.scopus.com/inward/record.url?scp=85119015321&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85119015321&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-21-3200
DO - 10.1158/0008-5472.CAN-21-3200
M3 - Review article
C2 - 34725132
AN - SCOPUS:85119015321
SN - 0008-5472
VL - 81
SP - 5396
EP - 5398
JO - Cancer Research
JF - Cancer Research
IS - 21
ER -